• Explore /
  • Poster
  • / The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with <em>HRAS </em>mutations.

The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations.

Abstract Poster

Authors

Robert Haddad

Robert I. Haddad

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Robert I. Haddad , Douglas Adkins , Lisa F. Licitra , Justine Yang Bruce , Maura L. Gillison , Myung-Ju Ahn , Ching-Yun Hsieh , Hung-Ming Wang , Amanda Psyrri , Jean-Pascal H. Machiels , Binaifer Balsara , Mollie Leoni , Kevin Joseph Harrington , Nabil F. Saba , Alan Loh Ho

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03719690

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS6087)

DOI

10.1200/JCO.2021.39.15_suppl.TPS6087

Abstract #

TPS6087

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Robert I. Haddad

First Author: A. Dimitrios Dimitrios Colevas

First Author: Colette Shen

First Author: Glenn J. Hanna